Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling-Reference-Cited by-同舟云学术

Urinary CD14 as a potential biomarker for benign prostatic hyperplasia - discovery by combining MALDI-TOF-based biostatistics and ESI-MS/MS-based stable-isotope labeling

Published:2011-02-15 Issue:3-4 Volume:5 Page:121-132
ISSN:1862-8346
Container-title:PROTEOMICS - Clinical Applications
language:en
Short-container-title:Prot. Clin. Appl.

Author:

Cheng Hong-Lin,Huang Hung-Jen,Ou Bing-Yuan,Chow Nan-Haw,Chen Yen-Wen,Tzai Tzong-Shin,Wu Chin-Jen,Chen Shu-Hui

Funder

National Science Council of Taiwan

Clinical Proteome Core

Medical College & Hospital in Departments of Urology and Pathology of the National Cheng Kung University Hospital

Publisher

Wiley

Subject

Clinical Biochemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/prca.201000011/fullpdf

Reference28 articles.

1. Prevention of benign prostatic hyperplasia disease;Marks;J. Urol.,2006

2. Treatment of men with minimally symptomatic benign prostatic hyperplasia − PRO: the argument in favor;Marks;Urology,2003

3. Medical therapy for asymptomatic men with benign prostatic hyperplasia: primum non nocere;Kaplan;Urology,2003

4. Prospects for urinary proteomics: exosomes as a source of urinary biomarkers;Hoom;Nephrology (Carlton),2005

5. Identification and proteomic profiling of exosomes in human urine;Pisitkun;Proc. Natl. Acad. Sci. USA,2004

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer proteomics: Application of case studies in diverse cancers;Proteomics;2023

2. MALDI-TOF/MS Analysis of Non-Invasive Human Urine and Saliva Samples for the Identification of New Cancer Biomarkers;Molecules;2022-03-16

3. Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics;Journal of Food and Drug Analysis;2019-04

4. Quantitative Mass Spectrometry-Based Proteomic Profiling for Precision Medicine in Prostate Cancer;Frontiers in Oncology;2017-11-07

5. The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer;Diagnostics;2016-07-18